Exploring Drug for Cancer Management

Supriya Kore; Srushti Yadav; Sarang Nirmale; Ashish Bhole; Shraddha Konda; Sanjana Kamble; Aniket Khot; Niranjan Kadam

doi:10.5281/zenodo.15476488

Review Paper | Open Access
Volume 02 | Issue 05 | Article Id IJSRT/250305095

Exploring Drug for Cancer Management
Supriya Kore* ¹ Srushti Yadav ² Sarang Nirmale ² Ashish Bhole ² Shraddha Konda ² Sanjana Kamble ² Aniket Khot ² Niranjan Kadam ²
¹Assistant professor Y. D. Mane Institute of Pharmacy, Kagal,
²Student, Y. D. Mane Institute of Pharmacy, Kagal

Abstract

Background Repurposing drugs for cancer treatment is a popular area of study right now. Theoretically, the repurposing strategy has various benefits over the acknowledged challenges of creating new molecular entities. It is generally claimed to be quicker, safer, simpler, and less expensive. Objectives This paper provides a thorough analysis of the different approaches used in drug repurposing, with a particular emphasis on using pharmaceuticals to treat cancer. We outline the antitumor characteristics of potential medications. We give a summary of the state of drug repurposing for cancer treatment in this paper, along with the obstacles that must be removed in order to fully reap the rewards of this strategy. It refers to the low-cost acceptance of repositioned medications for cancer treatment as conventional treatment for cancer reasons. We also stress how important it is to employ repurposed medications as part of a combination treatment plan.

Keywords

repurposed drugs, therapeutic, strategies, current candidates, potential drug, Apoptosis

Introduction

A disorder where cells proliferate abnormally and the cell cycle and apoptosis are not properly regulated is linked to cancer.[1] Global health is heavily burdened by cancer, which continues to be one of the major causes of mortality worldwide.1, 2 Numerous causes, including genetic mutations, environmental influences, a lack of physical exercise, a variety of lifestyles, and unstable behaviors relating to diet, smoking, and alcohol consumption, may contribute to the high prevalence of cancer.3, 4, 5, 6, and 7 Chemotherapy, radiation therapy, solid tumour surgery, or a mix of these are being used to treat different stages of different malignancies [2] [3] [4].

Reference

Doan TL, Pollastri M, Walters MA, G. I. Georg, the future of drug repositioning. Old Drugs, New Opportunities. Annu Rep Med Chem. 2011; 46:385–401. https://doi.org/10.1016/B978-0-12- 386009-5.00004-7. 3
Würth, R. et al. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov. Today 21, 190–199 (2016).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100,57–70 (2000). 69.
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144,646–674 (2011).
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommen dations. Nat. Rev. Drug Discov. 18,41–58 (2019).
Xue, H., Li, J., Xie, H. & Wang, Y. Review of drug repositioning approaches and resources. Int. J. Biol. Sci. 14, 1232–1244(2018).
Rudrapal M, Khairnar SJ, Jadhav AG. Drug repurposing (DR): An emerg ing approach in drug discovery, Drug Repurposing - Hypothesis. Mol Asp Ther Appl. 2020:1–20. https://doi.org/10.5772/intechopen.9 3196. 4
Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232–44.
Xue, H., Li, J., Xie, H. & Wang, Y. Review of drug repositioning approaches and resources. Int. J. Biol. Sci. 14, 1232–1244 (2018).
Schein, C. H. Repurposing approved drugs for cancer therapy. Br. Med. Bull. 137, 13–27 (2021).
Lotfi Shahreza, M., Ghadiri, N., Mousavi, S. R., Varshosaz, J. & Green, J. R. A review of network- based approaches to drug repositioning. Brief. Bioinform. 19, 878–892 (2018). 58.
Jarada, T. N., Rokne, J. G. & Alhajj, R. A review of computational drug reposi tioning: strategies, approaches, opportunities, challenges, and directions. J. Cheminform. 12, 46 (2020).
Vinay, D. S. et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35, S185–S198 (2015).
Issa, N. T., Stathias, V., Schürer, S. & Dakshanamurthy, S. Machine and deep learning approaches for cancer drug repurposing. Semin. Cancer Biol. 68, 132–142 (2021). 57.
Mottini, C., Napolitano, F., Li, Z., Gao, X. & Cardone, L. Computer- aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets. Semin. Cancer Biol. 68,59– 74 (2021). 56.
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommen dations. Nat. Rev. Drug Discov. 18,41–58 (2019).
Huang, Y. et al. Research progress, challenges, and breakthroughs of organoids as disease models. Front. Cell. Dev. Biol. 9, 740574 (2021).
Pushpakom, S. et al. Drug repurposing: progress, challenges and recommen dations. Nat. Rev. Drug Discov. 18,41–58 (2019).
Würth, R. et al. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov. Today 21, 190–199 (2016).
Lv, Z. & Guo, Y. Metformin and its benefits for various diseases. Front. Endocrinol. 11, 191 (2020)
H.K. Serajuddin, A.T. Serajuddin, Value of pharmaceuticals: ensuring the future of research and development, J. Am. Pharm.Assoc.46(2006)511–516.
Guo, Q. et al. A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study. Medicines 98, e16234(2019).
Jendrossek, V. Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett., 2013, 332(2), 313-324. [http://dx.doi.org/10.1016/j.canlet.20 11.01.012]21345578] [PMID]
Hwu, W.J. New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide. Oncology (Williston Park), 2000, 14(12) (Suppl. 13), 25-28. [PMID:11204670]
Lin, C. Y. et al. Simultaneous induction of apoptosis and necroptosis by Tan shinone IIA in human hepatocellular carcinoma HepG2 cells. Cell Death Discov. 2, 16065 (2016).
Xie L, Xu J, Sun X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO)progresssingafter
El Bairi K, Jabi R, Trapani D, et al. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut [published online ahead of print, 2020 May 24]. Expet Rev Clin Pharmacol2020:1e19.https://doi.org/ 10.1080/17512433.2020.1758063.
Guo, Q. et al. A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study. Medicines 98, e16234 (2019).
Felgenhauer, J. L. et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: a Children’s Oncology Group (COG) Phase II study NCT00061893. Pediatr. Blood Cancer 60, 409–414 (2013).
Dong, X. et al. Emodin: a review of its pharmacology, toxicity and pharmaco kinetics. Phytother. Res. 30, 1207–1218 (2016).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Pavlova, N. N., Zhu, J. & Thompson, C. B. The hallmarks of cancer metabolism: still emerging. Cell Metab. 34, 355–377 (2022).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100,57–70 (2000). 69.
chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Canc 2020;8(1): e000798.
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

Supriya Kore

Corresponding author

Assistant professor Y. D. Mane Institute of Pharmacy, Kagal